PLS3 and neoplasm: Tumor stage did not show a correlation with the expression levels of PLS3 (stage I+II—median: 5.78 [EU], range: 0.42–34.19 [EU]; stage III+IV—median: 6.58 [EU], range: 0–24.41 [EU]; p = ns) indicating that the differing PLS3 expression levels allow discrimination early CRC patients from IID patients and healthy donors (Figure 3B).